Legend Biotech Corporation (LEGN)

Market Cap	4.64B -23.2%
Revenue (ttm)	1.03B +64.0%
Net Income	-296.80M
EPS	-1.62
Shares Out	184.94M
PE Ratio	n/a
Forward PE	92.75
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,406,525
Open	21.71
Previous Close	21.17
Day's Range	21.69 - 26.72
52-Week Range	16.24 - 45.30
Beta	0.08
Analysts	Strong Buy
Price Target	63.08 (+151.62%)
Earnings Date	May 12, 2026

About LEGN

Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lym...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 5, 2020
• Employees: 2,965
• Stock Exchange: NASDAQ
• Ticker Symbol: LEGN
• Website: https://legendbiotech.com

Financial Performance

In 2025, Legend Biotech's revenue was $1.03 billion, an increase of 64.02% compared to the previous year's $627.30 million. Losses were -$296.80 million, 67.7% more than in 2024.

Analyst Summary

According to 13 analysts, the average rating for LEGN stock is "Strong Buy." The 12-month stock price target is $63.08, which is an increase of 151.62% from the latest price.

Price Target

$63.08

(151.62% upside)

Analyst Consensus: Strong Buy